MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Cerebrolysin Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Cerebrolysin is a porcine brain-derived peptide hydrolysate produced by standardized enzymatic breakdown of purified pig brain proteins, yielding a defined mixture of low-molecular-weight neuropeptides and free amino acids with neurotrophic factor-like activity. Manufactured by Ever Pharma in Austria, it has been used clinically across Europe, Russia, China, and parts of Asia for more than four decades for ischemic stroke, traumatic brain injury, and Alzheimer's-type dementia. Mechanistically, Cerebrolysin mimics endogenous neurotrophic factors such as BDNF, GDNF, NGF, and CNTF, supporting neuronal survival, neurite outgrowth, and synaptic plasticity while reducing excitotoxic and inflammatory damage in penumbral tissue around an ischemic core (PMID: 23076398). Cochrane and CARS-NIH meta-analyses suggest meaningful functional benefit when given early in moderate-to-severe ischemic stroke (PMID: 32196635). It is not FDA approved.
Reconstitute: Add 3 mL bacteriostatic water → 20 mg/mL concentration.
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: Lyophilized at room temperature (≤25 °C); reconstituted refrigerated (2–8 °C); do not freeze.
Half-life: Component peptides are cleared rapidly from plasma, but standard clinical regimens use 10-30 mL IV infusion daily for 10-21 day courses, relying on cumulative neurotrophic exposure rather than steady-state pharmacology.
Route: Intramuscular for low-dose outpatient use and intravenous infusion for stroke and TBI protocols; never intranasal or oral in registered indications.
Status: Approved and marketed across more than fifty countries including Austria, Germany, China, Russia, and Mexico for stroke, TBI, and dementia; not approved by the FDA or the UK MHRA.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
Interactive Cerebrolysin Syringe Calculator
Currently visualizing the 60 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 60mg dry powder in 3mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
1.3 Units (1 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 20 mg (20,000 mcg) | 100 units (1.0 mL) × 1 |
| Week 2 | 24 mg (24,000 mcg) | 60 units (0.6 mL) AM + 60 units (0.6 mL) PM |
| Week 3 | 28 mg (28,000 mcg) | 70 units (0.7 mL) AM + 70 units (0.7 mL) PM |
| Week 4+ | 32 mg (32,000 mcg) | 80 units (0.8 mL) AM + 80 units (0.8 mL) PM |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 60 mg vial.
Peptide Vials (Cerebrolysin, 60 mg each):
- check8 weeks ≈ 26 vials
- check12 weeks ≈ 42 vials
- check16 weeks ≈ 58 vials
Insulin Syringes (U‑100): Count based on injections per day (1–2 depending on dose).
- checkWeek 1 (1/day): 7 syringes
- checkWeeks 2–8 (2/day): 98 syringes
- check8 weeks total: 105 syringes
- check12 weeks total: 161 syringes
- check16 weeks total: 217 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check8 weeks (26 vials): 78 mL → 8 × 10 mL bottles
- check12 weeks (42 vials): 126 mL → 13 × 10 mL bottles
- check16 weeks (58 vials): 174 mL → 18 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- check8 weeks (105 injections): 210 swabs → recommend 3 × 100‑count boxes
- check12 weeks (161 injections): 322 swabs → recommend 4 × 100‑count boxes
- check16 weeks (217 injections): 434 swabs → recommend 5 × 100‑count boxes
Mechanism of Action (MOA)
Cerebrolysin is manufactured by Ever Neuro Pharma (Austria) through standardized enzymatic hydrolysis of porcine brain protein, producing a defined mixture of biologically active peptide fragments (15% of mass) and free amino acids (85% of mass) with molecular weights below 10 kilodaltons. The peptide fraction includes sequences with structural and functional similarity to endogenous neurotrophins, allowing the preparation to mimic the activity of brain-derived neurotrophic factor, nerve growth factor, ciliary neurotrophic factor, and glial-derived neurotrophic factor. Because intact neurotrophins cannot cross the blood-brain barrier in clinically meaningful quantities, Cerebrolysin's small peptide fragments offer a pharmacologic workaround: they cross the blood-brain barrier and exert pleiotropic neurotrophic, neuroprotective, and neuroplastic effects after parenteral administration. Mechanistically, Cerebrolysin activates several converging pathways. It enhances neuronal survival under hypoxic, excitotoxic, and oxidative stress by reducing calcium overload, suppressing free radical generation, and inhibiting calcium-dependent proteases. It modulates amyloid precursor protein processing, shifting the balance away from amyloidogenic cleavage in Alzheimer disease models, and reduces hyperphosphorylation of tau protein. It stimulates neurogenesis in the subventricular zone and dentate gyrus, supports synaptogenesis through enhanced dendritic arborization, and increases expression of GAP-43 and synaptic proteins. In stroke models, Cerebrolysin reduces infarct volume, attenuates blood-brain barrier disruption, and accelerates motor and cognitive recovery. Cerebrolysin is delivered parenterally because oral bioavailability of its peptide fraction is negligible. Intramuscular doses of 1–5 mL can be self-administered; intravenous infusion at 10–30 mL is delivered slowly over 15–60 minutes diluted in saline or Ringer's solution, with rapid bolus avoided to prevent transient flushing or vasomotor symptoms. Plasma kinetics are difficult to characterize because Cerebrolysin is a mixture rather than a single molecule, but functional CNS effects on EEG and cerebral metabolism are measurable within hours and persist for weeks after a full treatment course. Standard clinical regimens are 10-day to 4-week cycles repeated quarterly or biannually, with cumulative dose scaled to indication. Acute stroke uses 30 mL IV daily for 10–21 days (CARS, CASTA protocols); vascular dementia uses 20 mL IV daily for 5 days/week across two 4-week cycles; mild cognitive impairment commonly uses 5–10 mL IM daily across 4-week courses. Importantly, Cerebrolysin is a biologically standardized preparation, and the regulatory dossier supporting its use in stroke and dementia rests on more than 60 randomized trials and several Cochrane reviews evaluating its activity in cerebrovascular disease.
Clinical Trial Efficacy Highlights
- starThe CARS randomized double-blind trial (Cerebrolysin and Recovery After Stroke) treated 208 patients with moderate to severe acute ischemic stroke with 30 mL/day Cerebrolysin or placebo for 21 days starting 24–72 hours post-onset. The treatment arm showed superior recovery on the Action Research Arm Test and 90-day functional outcomes [4].
- starThe CASTA trial (Cerebrolysin Acute Stroke Treatment in Asia) randomized 1070 patients to 30 mL IV Cerebrolysin daily or placebo for 10 days; pre-specified analysis in severe stroke (NIHSS >12) showed a favorable shift in NIHSS recovery and modified Rankin Scale at 90 days [3].
- starIn vascular dementia, Guekht and colleagues reported that 20 mL IV Cerebrolysin daily for two 4-week cycles produced clinically relevant improvements on ADAS-cog and CIBIC-plus versus placebo in a randomized double-blind multicenter trial [5].
- starIn Alzheimer disease, a meta-analysis of six randomized trials by Cui et al. found that Cerebrolysin 10–30 mL IV/IM for 4 weeks produced significant cognitive improvement on ADAS-cog and global function measures compared with placebo, with effects sustained at 6 months [6].
- starAn observational retrospective study of minimally conscious state patients showed that 10 mL/day Cerebrolysin for at least 20 days improved Coma Recovery Scale-Revised scores compared to matched controls receiving rehabilitation alone [7].
- starTraumatic brain injury trials in moderate to severe TBI showed reduced ICU stay and improved cognitive recovery at 50 mL/day Cerebrolysin for 10 days plus 10 mL/day for 20 days, with effects on attention, executive function, and memory at 3-month follow-up.
- starCochrane and meta-analytic reviews note that despite methodological heterogeneity, Cerebrolysin consistently improves global outcome and disability measures in acute ischemic stroke and vascular dementia, with a number-needed-to-treat in the range of 7–9 across pooled data.
- starPediatric use in neurodevelopmental disorders is widespread in Eastern Europe and Russia at 1–5 mL IM daily, though Western evidence is limited; safety in this population has been documented across decades of practice without major adverse signals.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningThe most common adverse effects of Cerebrolysin are transient dizziness, mild flushing, sensation of warmth, or sweating during or shortly after infusion, especially when administered too rapidly; slowing the infusion rate generally resolves these symptoms.
- warningInjection site reactions including pain, redness, or induration occur with intramuscular dosing and are dose-dependent; rotating injection sites and limiting per-site volume to under 5 mL minimizes local discomfort.
- warningHeadache and mild gastrointestinal upset (nausea, loss of appetite) have been reported in fewer than 5% of patients and typically resolve without dose reduction.
- warningHypersensitivity reactions are rare but reported, including urticaria and angioedema; Cerebrolysin is contraindicated in patients with known hypersensitivity to porcine proteins or to any component of the formulation.
- warningStatus epilepticus has been described in case reports following high-dose IV administration in patients with active seizure disorders; caution is warranted in patients with uncontrolled epilepsy, and slower titration is recommended.
- warningCerebrolysin should not be co-administered with antidepressants or MAO inhibitors in the same infusion line because of the free amino acid content; separate administration is unproblematic.
- warningPatients with severe renal impairment may require dose reduction, although formal pharmacokinetic data in renal disease are limited.
- warningNo teratogenicity has been documented in animal reproductive studies, but human pregnancy data are insufficient; use during pregnancy and lactation should follow individual benefit-risk assessment.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Cerebrolysin dosage?expand_more
Adult dosing ranges from 5 to 30 mL daily, depending on indication. Acute stroke protocols use 30 mL IV daily for 10–21 days. Vascular dementia uses 20 mL IV daily for 4-week cycles. Maintenance and outpatient use is typically 5–10 mL IM daily for 4-week courses, repeated quarterly.
How is Cerebrolysin administered?expand_more
Cerebrolysin is delivered parenterally — intramuscular injection (1–5 mL doses) or slow intravenous infusion (10–30 mL diluted in 100–250 mL saline or Ringer's, over 15–60 minutes). Oral administration is not effective because the peptide fraction is degraded in the gut.
Can Cerebrolysin be stacked?expand_more
Cerebrolysin is commonly combined with cholinesterase inhibitors in Alzheimer disease and with antiplatelet or anticoagulant stroke regimens. It should not be infused in the same line as antidepressants or MAO inhibitors. Combination with other neurotrophic peptides is empirical.
What are the side effects of Cerebrolysin?expand_more
Most common are transient flushing, dizziness, and warmth during infusion, usually preventable by slowing the rate. Injection-site irritation occurs with IM use. Hypersensitivity to porcine protein is the principal contraindication; rare seizure exacerbation has been reported.
Is Cerebrolysin FDA approved?expand_more
No. Cerebrolysin is approved as a prescription drug in over 50 countries including Austria, Germany, Russia, China, and across Eastern Europe and Asia, but it is not FDA approved and is not legally marketed in the United States. EMA has not approved a centralized authorization.
Academic References & Study Citations
Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia. Stroke. 2012;43(3):630-636. View Scientific Paper →
Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016;47(1):151-9. View Scientific Paper →
Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20(4):310-8. View Scientific Paper →
Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;11(11):CD008900. View Scientific Paper →
Alvarez XA, Cacabelos R, Sampedro C, et al. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res. 2011;8(5):583-91. View Scientific Paper →
Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. View Scientific Paper →
Vester JC, Buzoianu AD, Muresanu DF, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(11):4531-4541. View Scientific Paper →
Formichi P, Radi E, Battisti C, et al. Cerebrolysin administration as a treatment for preventing neuronal damage in patients with neurodegenerative disorders. J Cell Physiol. 2012;227(5):2202-2209. View Scientific Paper →
Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm. 2001;108(4):459-73. View Scientific Paper →
Pruccoli J, Esposito S, Sanvito L, et al. Effects of Cerebrolysin in patients with minimally conscious state after stroke: an observational retrospective clinical study. Front Neurol. 2019;10:803. View Scientific Paper →